United Kingdom Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and Forecasts, 2026-2034

United Kingdom Cell and Gene Therapy Manufacturing QC Market Size

The United Kingdom Cell and Gene Therapy Manufacturing QC Market size was valued at USD 428 million in 2025 and is projected to grow from USD 489.63 million in 2026 to USD 1436.41 million by 2034 at a CAGR of 14.4% during the forecast period 2026–2034.

The United Kingdom (UK) is one of the leading players in this sector, with substantial investments in research, development, and commercialization of advanced therapies.

The UK's strong regulatory framework, supportive government policies, and growing biotech ecosystem have made it a crucial hub for cell and gene therapy manufacturing and quality control (QC)., thereby driving market expansion.

Therapy Type Insights

The UK cell and gene therapy manufacturing QC market is segmented by therapy type, scale, mode, workflow, process, end-user, and technology type.

Cell therapy dominates the therapy type segment and is expected to augment at a CAGR of 24.7%. The cell therapy segment in the UK is experiencing rapid growth due to increasing clinical trials for cancer, genetic, and autoimmune disorders. The UK's strong research ecosystem, government funding, and world-class healthcare infrastructure have accelerated the development of advanced cell therapies. These therapies' shift from experimental to commercial stages is driving demand for enhanced manufacturing and QC processes.

Request Customizationto receive a tailored report.

Scale Insights

Pre-commercial/ R&D manufacturing dominates the scale segment and is estimated to grow at a CAGR of 27.1%. The pre-commercial/R&D manufacturing scale segment is growing in the UK due to the surge in clinical trials and early-stage research for cell and gene therapies. Companies are investing in R&D-scale manufacturing to ensure product quality and regulatory compliance during the developmental phase, allowing for a smooth transition to large-scale commercial production once therapies receive regulatory approval.

Mode Insights

In-house manufacturing is estimated to own the mode segment and is anticipated to expand at a CAGR of 26.3%. The in-house manufacturing mode segment is expanding in the United Kingdom cell and gene therapy market due to companies seeking greater control over production quality, intellectual property protection, and faster product development cycles. Establishing in-house capabilities allows companies to streamline QC processes, reduce reliance on external manufacturers, and maintain compliance with stringent regulatory requirements, particularly for personalized therapies.

Speak to an Analystto discuss market opportunities.

Country Insights

The UK region is a key player in the European market. London, Oxford, and Cambridge form the 'Golden Triangle' of biotech innovation, hosting leading research institutions and companies specializing in advanced therapies. London is home to major pharma companies like GlaxoSmithKline, and Oxford and Cambridge house several pioneering biotech firms, including Adaptimmune and Oxford Biomedica, which are leading the way in cell and gene therapy development. Additionally, the Cell and Gene Therapy Catapult's manufacturing facility in Stevenage has become a major hub for advanced therapy production and QC, driving significant growth in the region.

Scotland is also emerging as a key region, with the Scottish National Blood Transfusion Service (SNBTS) establishing a center for advanced cell therapy manufacturing. Furthermore, Northern Ireland and Wales, though smaller markets are beginning to invest in cell and gene therapy research, with government support aimed at boosting local biotech ecosystems. Moreover, the UK's strategic location and world-class research infrastructure, combined with post-Brexit efforts to streamline international collaborations, position the region as a leading hub for this industry.

List of Key and Emerging Players in United Kingdom Cell and Gene Therapy Manufacturing QC Market